According to Jason Luke, MD, FACP, there is still room to improve response rates in CSCC treatment, but there is excitement surrounding future of treatment outcomes.
Approval Alert | Cosibelimab in Cutaneous Squamous Cell Carcinoma
Objective response data from the CK-301-101 trial supports cosibelimab’s approval by the FDA, according to Jason J. Luke, MD, FACP.
Cosibelimab has been approved by the FDA as a treatment for patients with cutaneous squamous cell carcinoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
2
FDA Approves Revumenib in R/R NPM1-Mutant AML
3
Convergent and Divergent Signaling Pathways in Cancer: A Dual-Axis Model for Adaptive Precision Oncology
4
ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC
5
